The Medicines Patent Pool and Pharco Pharmaceuticals Sign Licence for Promising Hepatitis C Drug Candidate Ravidasvir

AMSTERDAM, April 21, 2017 /PRNewswire/ -- Agreement seeks to improve health options for hepatitis C patients in low- and middle-income countries The Medicines Patent Pool (MPP) announced a new licence and technology transfer agreement with Egyptian company Pharco Pharmaceuticals for ravidasvir (RAV), an investigational direct-acting antiviral (DAA) with the potential of working across all six major hepatitis C genotypes. The agreement, signed on the sidel

Mylan enters MPP agreement over affordable hepatitis C generics

Mylan has entered into a sub-licensing agreement with the Medicines Patent Pool (MPP), a UN-backed public health organisation, to expand access to chronic hepatitis C medicines in developing countries. Under the agreement, announced yesterday, November 28, Mylan will produce and market a generic version of Bristol-Myers Squibb’s Daklinza (daclatasvir). The generic drug will be distributed in 112 low and middle income countries. Source:

The Medicines Patent Pool Signs First Sub-licences for Hepatitis C Medicine Daclatasvir

GENEVA, January 20, 2016 /PRNewswire/ --Four companies to help speed access to curative direct-acting antiviral in 112 low- and middle-income countries The Medicines Patent Pool (MPP) announced its first round of sub-licences for the generic production of Bristol-Myers Squibb's daclatasvir, a novel direct-acting antiviral that is proven to help cure multiple genotypes of the hepatitis C virus. Generic companies Cipla, Emcure, Hetero and Natco have signed n

MPP announces expansion of mandate to hepatitis C and TB medicines

MPP's voluntary licensing work could benefit millions of patients in low- and middle-income countriesThe Medicines Patent Pool (MPP), the world's only voluntary licensing mechanism in public health, announced an expansion of its mandate today to hepatitis C and tuberculosis medicines. The UNITAID Executive Board, meeting November 4-5 in Geneva, approved the MPP's proposals to improve access to both life-saving direct acting antivirals (DAAs) to treat hepat